Long-term follow-up of diabetic macular edema treated with dexamethasone implant: a real-life study.
Adult
Aged
Aged, 80 and over
Cohort Studies
Dexamethasone
/ administration & dosage
Diabetic Retinopathy
/ drug therapy
Drug Implants
Female
Follow-Up Studies
Humans
Intraocular Pressure
/ drug effects
Intravitreal Injections
Macular Edema
/ drug therapy
Male
Middle Aged
Retrospective Studies
Visual Acuity
/ drug effects
Central macular thickness
Corticosteroids
Dexamethasone implant
Diabetic macular edema
Diabetic retinopathy
Journal
Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
26
04
2020
accepted:
17
06
2020
pubmed:
14
7
2020
medline:
15
12
2020
entrez:
14
7
2020
Statut:
ppublish
Résumé
To evaluate the efficacy and safety of intravitreal dexamethasone implant (DEX-implant) for diabetic macular edema (DME) in real-life practice with an extended follow-up for up to 5 year. This multicentric retrospective study reviewed 227 eyes of 152 patients with DME treated by DEX-implant. Main outcome measures included changes in best corrected visual acuity (BCVA), central macular thickness (CMT), time to retreatment and incidence of adverse effects. The mean number of DEX-implant received by patients was 2.6 (± 2.2) with a mean (SD) follow-up of 20.1 (± 15.8) months, median [IQR] 15.8 [7.4-30.1]. The mean time of retreatment was 6.9 months. The mean maximal BCVA gain during follow-up was 12.3 (± 12.7) letters. A gain of ≥ 5, ≥ 10 and ≥ 15 letters from baseline BCVA was obtained for 71.8%, 48.9% and 34.8% of eyes, respectively. A total of 62.6% of eyes presented a significant anatomical response (decrease of CMT ≥ 20%), and DME was resolved (absence of cystoid macular spaces on OCT) in 37% of cases at the end of the follow-up. A transient increase in intraocular pressure ≥ 25 mmHg occurred in 14.1% of eyes, and cataract surgery was performed for 49.1% of the phakic eyes during the follow-up. Four eyes developed a proliferative diabetic retinopathy. This large cohort study showed favorable long-term outcomes when using DEX-implant, which provides substantial long-term benefits in the treatment of DME in real life.
Identifiants
pubmed: 32656710
doi: 10.1007/s00592-020-01561-1
pii: 10.1007/s00592-020-01561-1
doi:
Substances chimiques
Drug Implants
0
Dexamethasone
7S5I7G3JQL
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1413-1421Références
Klein R, Klein BE, Moss SE et al (1984) The Wisconsin epidemiologic study of diabetic retinopathy IV Diabetic macular edema. Ophthalmology 91:1464–1474. https://doi.org/10.1016/s0161-6420(84)34102-1
doi: 10.1016/s0161-6420(84)34102-1
pubmed: 6521986
NCD Risk Factor Collaboration (NCD-RisC) (2016) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet Lond Engl 387:1513–1530. https://doi.org/10.1016/S0140-6736(16)00618-8
doi: 10.1016/S0140-6736(16)00618-8
Boyer DS, Yoon YH, Belfort R et al (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904–1914. https://doi.org/10.1016/j.ophtha.2014.04.024
doi: 10.1016/j.ophtha.2014.04.024
pubmed: 24907062
Nguyen QD, Brown DM, Marcus DM et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789–801. https://doi.org/10.1016/j.ophtha.2011.12.039
doi: 10.1016/j.ophtha.2011.12.039
pubmed: 22330964
Heier JS, Korobelnik J-F, Brown DM et al (2016) Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 123:2376–2385. https://doi.org/10.1016/j.ophtha.2016.07.032
doi: 10.1016/j.ophtha.2016.07.032
pubmed: 27651226
Boyer DS, Nguyen QD, Brown DM et al (2015) Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology 122:2504–2513.e1. https://doi.org/10.1016/j.ophtha.2015.08.006
doi: 10.1016/j.ophtha.2015.08.006
pubmed: 26452713
Brown DM, Schmidt-Erfurth U, Do DV et al (2015) Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 122:2044–2052. https://doi.org/10.1016/j.ophtha.2015.06.017
doi: 10.1016/j.ophtha.2015.06.017
pubmed: 26198808
Kodjikian L, Bellocq D, Mathis T (2018) Pharmacological management of diabetic macular edema in real-life observational studies. BioMed Res Int 2018:8289253. https://doi.org/10.1155/2018/8289253
doi: 10.1155/2018/8289253
pubmed: 30246026
pmcid: 6136521
Fraser-Bell S, Lim LL, Campain A et al (2016) Bevacizumab or dexamethasone implants for DME: 2-year results (The BEVORDEX Study). Ophthalmology 123:1399–1401. https://doi.org/10.1016/j.ophtha.2015.12.012
doi: 10.1016/j.ophtha.2015.12.012
pubmed: 26783096
Malclès A, Dot C, Voirin N et al (2017) Real-life study in diabetic macular edema treated with dexamethasone implant: the reldex study. Retina Phila Pa 37:753–760. https://doi.org/10.1097/IAE.0000000000001234
doi: 10.1097/IAE.0000000000001234
Malclès A, Dot C, Voirin N et al (2017) Safety of intravitreal dexamethasone implant (OZURDEX): the SAFODEX study. Incidence and Risk Factors of Ocular Hypertension. Retina Phila Pa 37:1352–1359. https://doi.org/10.1097/IAE.0000000000001369
doi: 10.1097/IAE.0000000000001369
Poli M, Denis P, Dot C, Nordmann J-P (2017) Ocular hypertension after intravitreal injection: screening and management. J Fr Ophtalmol 40:e77–e82. https://doi.org/10.1016/j.jfo.2017.01.003
doi: 10.1016/j.jfo.2017.01.003
pubmed: 28284658
Yoon YH, Kim JW, Lee JY et al (2018) Dexamethasone intravitreal Implant for early treatment and retreatment of macular edema related to branch retinal vein occlusion: the multicenter COBALT study. Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd 240:81–89. https://doi.org/10.1159/000487547
doi: 10.1159/000487547
Lo Giudice G, Avarello A, Campana G, Galan A (2018) Rapid response to dexamethasone intravitreal implant in diabetic macular edema. Eur J Ophthalmol 28:74–79. https://doi.org/10.5301/ejo.5000989
doi: 10.5301/ejo.5000989
pubmed: 28708221
Busch C, Zur D, Fraser-Bell S et al (2018) Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol 55:789–796. https://doi.org/10.1007/s00592-018-1151-x
doi: 10.1007/s00592-018-1151-x
pubmed: 29730822
Bellocq D, Akesbi J, Matonti F et al (2018) The pattern of recurrence in diabetic macular edema treated by dexamethasone implant: the PREDIAMEX study. Ophthalmol Retina 2:567–573. https://doi.org/10.1016/j.oret.2017.10.016
doi: 10.1016/j.oret.2017.10.016
pubmed: 31047610
Tufail A, Lightman S, Kamal A et al (2018) Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis. Clin Ophthalmol Auckl NZ 12:2519–2534. https://doi.org/10.2147/OPTH.S181256
doi: 10.2147/OPTH.S181256
Kodjikian L, Bellocq D, Bandello F et al (2019) First-line treatment algorithm and guidelines in center-involving diabetic macular edema. Eur J Ophthalmol 29:573–584. https://doi.org/10.1177/1120672119857511
doi: 10.1177/1120672119857511
pubmed: 31238719
Calvo P, Ferreras A, Al Adel F et al (2018) Effect of an intravitreal dexamethasone implant on diabetic macular edema after cataract surgery. Retina Phila Pa 38:490–496. https://doi.org/10.1097/IAE.0000000000001552
doi: 10.1097/IAE.0000000000001552
Mitchell P, McAllister I, Larsen M et al (2018) Evaluating the impact of intravitreal aflibercept on diabetic retinopathy progression in the VIVID-DME and VISTA-DME studies. Ophthalmol Retina 2:988–996. https://doi.org/10.1016/j.oret.2018.02.011
doi: 10.1016/j.oret.2018.02.011
pubmed: 31047501
Virgili G, Parravano M, Evans JR et al (2018) Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev 10:CE007419. https://doi.org/10.1002/14651858.CD007419.pub6
doi: 10.1002/14651858.CD007419.pub6
Weiss M, Sim DA, Herold T et al (2018) Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina Phila Pa 38:2293–2300. https://doi.org/10.1097/IAE.0000000000001892
doi: 10.1097/IAE.0000000000001892
Borrelli E, Sarraf D, Freund KB, Sadda SR (2018) OCT angiography and evaluation of the choroid and choroidal vascular disorders. Prog Retin Eye Res. https://doi.org/10.1016/j.preteyeres.2018.07.002
doi: 10.1016/j.preteyeres.2018.07.002
pubmed: 30059755
Couturier A, Rey P-A, Erginay A et al (2019) Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti-vascular endothelial growth factor. Ophthalmology. https://doi.org/10.1016/j.ophtha.2019.06.022
doi: 10.1016/j.ophtha.2019.06.022
pubmed: 31383483